Download PDF
Osteologie 2011; 20(04): 7
DOI: 10.1055/s-0037-1620019
Vitamin D
Schattauer GmbH

Literatur

J. Reichrath
Further Information

Publication History

Publication Date:
30 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • Literatur

  • 1 Holick MF. Vitamin D deficiency. NEJM 2007; 357: 266-281.
    CrossrefPubMedGoogle Scholar
  • 2 Trémezaygues L, Reichrath J. The significance of vitamin D metabolism in human skin: an update. Hautarzt 2010; 61 (06) 478, 480-486.
    Google Scholar
  • 3 von Domarus C, Amling M. Volkswirtschaftliche Bedeutung einer Vitamin-D-Anreicherung von Lebensmitteln - eine gesundheitsökonomische Markov-Analyse unter besonderer Berücksichtigung hüftgelenksnaher Frakturen. Osteologie 2009; 18: 112-124.
    Article in Thieme ConnectGoogle Scholar
  • 4 Hintzpeter B. et al. Vitamin D status and health correlates among German adults. Eur J Clin Nutr 2008; 62 (09) 1079-1089.
    CrossrefPubMedGoogle Scholar
  • 5 Lehmann B, Genehr T, Knuschke P. et al. UVB-induced conversion of 7-dehydrocholesterol to 1alpha25-dihydroxyvitamin D3 in an in vitro human skin equivalent model. J Invest Dermatol 2001; 117: 1179-1185.
    CrossrefPubMedGoogle Scholar
  • 6 Holick MF, MacLaughlin JA, Clark MB, Holick SA. Photosynthesis of previtamin D3 in human skin and the physiologic consequences. Science 1980; 210: 203-205.
    CrossrefPubMedGoogle Scholar
  • 7 Bikle DD, Neumanic MK, Gee E, Elias P. 1,25-Dihydroxyvitamin D3 production by human keratinocytes. J Clin Invest 1986; 78: 557-566.
    CrossrefPubMedGoogle Scholar
  • 8 Lehmann B, Tiebel O, Meurer M. Expression of vitamin D3 25-hydroxylase (CYP27) mRNA after induction by vitamin D3 or UVB radiation in keratinocytes of human skin equivalents-a preliminary study. Arch Dermatol Res 1999; 291: 507-510.
    CrossrefPubMedGoogle Scholar
  • 9 Henry HL. The 25(OH)D/1,25(OH)2D3-24R-hydroxylase: a catabolic or biosynthetic enzyme?. Steroids 2001; 66 3-5 391-398.
    CrossrefPubMedGoogle Scholar
  • 10 Gniadecki R. Stimulation versus inhibition of keratinocyte growth by 1,25-Dihydroxyvitamin D3: dependence on cell culture conditions. J Invest Dermatol 1996; 106 (03) 510-516.
    CrossrefPubMedGoogle Scholar
  • 11 Reichrath J, Müller SM, Kerber A. et al. Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin. J Am Acad Dermatol 1997; 36: 19-28.
    CrossrefPubMedGoogle Scholar
  • 12 Reichrath J, Perez A, Chen TC. et al. The effectiveness of topical 1,25-dihydroxyvitamin D3 (1,25[OH]2D3) application in the treatment of psoriasis: an immunohistological evaluation. Acta Derm Venereol (Stockh) 1997; 77: 268-272.
    Google Scholar
  • 13 Holick MF, Reichrath J. Clinical utility of 1,25-Dihydroxyvitamin D3 and its analogues for the treatment of psoriasis. In: Holick MF. ed. Vitamin D: Physiology, molecular biologic and clinical aspects. Totowa New York: The Humana Press Inc; 1999: 357-373.
    Google Scholar
  • 14 Van Etten E, Decallone B, Verlinden L. et al. Analogs of 1α,25-Dihydroxyvitamin D3 as pluripotent immunomodulators. J Cell Biochem 2003; 88: 223-226.
    CrossrefPubMedGoogle Scholar
  • 15 Griffin M, Kumar R. Effects of 1α,25-Dihydroxyvitamin D3 and its analogs on dendritic cell function. J Cell Biochem 2003; 88: 323-326.
    CrossrefPubMedGoogle Scholar
  • 16 Adorini L, Penna G, Giarratana N, Uskokovic M. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. J Cell Biochem 2003; 88: 227-233.
    CrossrefPubMedGoogle Scholar
  • 17 Sigmundsdottir H, Pan J, Debes GF. et al. DCs metabolize sunlight-induced vitamin D3 to „program” T cell attraction to the epidermal chemokine CCL27. Nat Immunol 2007; 08 (03) 285-293.
    CrossrefPubMedGoogle Scholar
  • 18 Solvoll K, Soyland E, Sandstad B, Drevon CA. Dietary habits among patients with atopic dermatitis. Eur J Clin Nutr 2000; 54 (02) 93-97.
    CrossrefPubMedGoogle Scholar
  • 19 Katayama I, Minatohara K, Yokozeki H, Nishioka K. Topical vitamin D3 downregulates IgE-mediated murine biphasic cutaneous reactions. Int Arch Allergy Immunol 1996; 111 (01) 71-76.
    CrossrefPubMedGoogle Scholar
  • 20 Gombard HF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J 2005; 19 (09) 1067-1077.
    CrossrefPubMedGoogle Scholar
  • 21 Wang T-T, Nestel FP, Bourdeau V. et al. Cutting edge: 1,25-Dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004; 173 (05) 2909-2912.
    CrossrefPubMedGoogle Scholar
  • 22 Weber G, Heilborn JD, Chamorro CIJimenez. et al. Vitamin D induces the antimicrobial protein hCAP18 in human skin. J Invest Dermatol 2005; 124 (05) 1080-1082.
    CrossrefPubMedGoogle Scholar
  • 23 Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol 2004; 75: 39-48.
    CrossrefPubMedGoogle Scholar
  • 24 Zaiou M, Nizet V, Gallo RL. Antimicrobial and protease inhibitory functions of the human cathelicidin (hCAP18/LL-37) prosequence. J Invest Dermatol 2003; 120: 810-816.
    CrossrefPubMedGoogle Scholar
  • 25 Dorschner RA, Pestonjamasp VK, Tamakuwala S. Cutaneous injury induces the release of cathelicidin antimicrobial peptides active against group A Streptococcus. J Invest Dermatol 2001; 117: 91-97.
    CrossrefPubMedGoogle Scholar
  • 26 Frohm MNilsson, Sandstedt B, Sørensen O. et al. The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6. Infect Immun 1999; 67: 2561-2566.
    PubMedGoogle Scholar
  • 27 Peric M, Koglin S, Dombrowski Y. et al. Vitamin D analogs differentially control antimicrobial peptide/”alarmin” expression in psoriasis. PLoS One 2009; 04 (07) e6340.
    CrossrefPubMedGoogle Scholar
  • 28 Osterlind A, Tucker MA, Stone BJ, Jensen OM. The Danish case-control study of cutaneous malignant melanoma. II importance of UV-light exposure. Int J Cancer 1988; 42: 319-324.
    CrossrefPubMedGoogle Scholar
  • 29 Bastuji-Garin S, Diepgen TL. Cutaneous malignant melanoma, sun exposure and sunscreen use: epidemiological evidence. Br J Dermatol 2002; 146 (Suppl. 61) 24-30.
    CrossrefPubMedGoogle Scholar
  • 30 Garland CF, Comstock GW, Garland FC. et al. Serum 25-hydroxyvitamin D and colon cancer: eight year prospective study. Lancet 1989; 02 8673 1176-1178.
    Google Scholar
  • 31 Grant WB. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002; 94: 1867-1875.
    CrossrefPubMedGoogle Scholar
  • 32 Nürnberg B, Gräber S, Gärtner B. et al. Reduced serum 25-Hydroxyvitamin D levels in stage IV melanoma patients. Anticancer Res 2009; 29: 3669-3674.
    Google Scholar
  • 33 Newton-Bishop JA, Beswick S, Randerson-Moor J. et al. Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma. J Clin Oncol 2009; 27 (32) 5439.
    CrossrefPubMedGoogle Scholar
  • 34 Hutchinson PE, Osborne JE, Lear JT. et al. Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin Cancer Res 2000; 06 (02) 498-504.
    Google Scholar
  • 35 Reichrath J. Protecting against adverse effects of sun protection?. J Am Acad Dermatol 2003; 49 (06) 1204-1206.
    CrossrefPubMedGoogle Scholar
  • 36 Reichrath J, Querings K. Vitamin D deficiency needs to be detected and treated in solid-organ transplant recipients (OTRs). Dermatol Surg 2004; 30 (12) 1501-1501.
    PubMedGoogle Scholar
  • 37 Querings K, Reichrath J. A plea for detection and treatment of vitamin D deficiency in patients under photoprotection, including patients with xeroderma pigmentosum and basal cell nevus syndrome. Cancer Cause Control 2004; 15 (02) 219.
    CrossrefPubMedGoogle Scholar